SEATTLE, May 28, 2021, (MEDGADGET) — Overview
A side effect of external beam ionizing radiation is radiodermatitis, also known as x-ray dermatitis, radiation dermatitis, radiation-induced skin responses, or radiation damage. Radiotherapy, which is used to cure tumors and other illnesses, is one of the leading causes of radiodermatitis. Nuclear attacks and earthquakes may also trigger this disease.
The global radiodermatitis market is priced at US$ 360.5 million and is projected to rise to US$ 472.8 million by the end of 2027.
For More Information, Request Sample Copy Of Business Report: https://www.coherentmarketinsights.com/insight/request-pdf/3881
Over the projected period, increasing cancer incidence is projected to boost the global radiodermatitis market. According to the American Cancer Society, there will be 1,762,450 new cancer patients diagnosed and 606,880 cancer deaths in the United States in 2019.
Furthermore, increased research and development work to develop newer therapies for radiodermatitis treatment is expected to augment growth of the global radiodermatitis market. Kannalife, Inc., filed a new U.S. Patent in December 2019 for its patented and experimental CBD-like molecules for the treatment of radiodermatitis and other skin disorders.
In terms of value, topical agents dominated the global radiodermatitis market in 2019, accounting for 70.5% of the market, supplemented by dressing and oral medication segments, respectively.
Growth of the global radiodermatitis market is projected to be hampered by the advent of improved radiation therapy devices. The severity and likelihood of developing radiodermatitis may be determined by the patient or the procedure. The form and nature of the radiation beam, as well as the position and scale of the treatment field, are both treatment-related considerations.
By more specifically treating tumors, advanced radiotherapy techniques such as intensity-modulated radiation therapy (IMRT) and proton therapy may reduce the risk of radiodermatitis. Such a situation is likely to stifle demand expansion.
Furthermore, high-cost dressings such as honey-impregnated and silicone dressings are likely to restrain market growth.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/3881
For players in the global radiodermatitis market, R&D in radiodermatitis is projected to provide lucrative growth opportunities. In the second half of 2020, Jay Pharma, plans to start a pilot study focused on radiodermatitis.
Furthermore, spending money to raise concern about radiation-induced skin damage among caregivers and patients in regions with ordinary standard care procedures, such as Asia Pacific, Latin America, and the Middle East and Africa, is expected to help in expansion of the market.
The global radiodermatitis market was worth US$ 346.9 million in 2019 and is expected to grow to US$ 472.8 million by 2027 with a CAGR of 3.9% over the forecast period (2020-2027).
For the prevention of radiodermatitis, topical medications are often prescribed. Despite the lack of evidence to justify their application, topical steroids and emollients are the most often used agents for the treatment of radiodermatitis around the world. Alternative herbal remedies include aloe vera gel. Gels are effective in seborrheic areas, while creams are effective in areas other than skin folds and seborrheic areas.
In the treatment of radiodermatitis, over-the-counter (OTC) medications are favored over prescription products. This is due to word-of-mouth advice and the quick availability of OTC drugs both online and in local pharmacies. Hydrophilic is an easily available OTC that creams sooth redness and itching.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/radiodermatitis-market-3149
Value Chain Analysis
The sourcing of raw materials, such as API for oral medication and silicone/hydrogel for silicone and hydrogel dressings, is the first step in the supply chain for radiation dermatitis products. The content goes into R&D, processing, and the supply chain before being sold to end-users in laboratories, hospitals, and convenience stores (brick & mortar as well as online stores).
Key companies contributing in the global radiodermatitis market are Intermed Pharmaceuticals, ConvaTec Group PLC, Smith & Nephew Plc, BMG Pharma S.r.l., Jay Pharma, Kannalife, Inc., Acelity, Inc. (3M), Stratpharma AG, Integra LifeSciences Holdings Corporation (DermaSciences Inc.), Molnlycke Health Care.
The market’s major players are focusing on M&A tactics to broaden their product range.
3M purchased Acelity, Inc. and its KCI subsidiaries in October 2019.
Rebound Therapeutics, a maker of single-use medical devices that allow minimally invasive access in neurosurgery, was acquired by Integra LifeSciences Holdings Corporation in September 2019.
Other Related Reports:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027